Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
复制标题
DOI：
10.1038/nrc3432
复制
发表时间：
2013-04
期刊：
影响因子：
--
通讯作者：
Kaye SB
中科院分区：
文献类型：
--
作者：
Kipps E;Tan DS;Kaye SB
恶性腹水对卵巢癌的治疗提出了相当大的临床挑战，但也为转化研究提供了丰富的机会。腹水及其细胞成分的可及性使其成为研究预后和预测生物标志物、药效学标志物和分子谱分析的肿瘤组织的极好来源。在这篇观点文章中，我们讨论了我们对其病理生理学的理解的最新进展，新方法的发展来表征其分子特征，以及这些发现如何用于改善恶性腹水的治疗，特别是在卵巢癌的背景下。
Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumour tissue for the investigation of prognostic and predictive biomarkers, pharmacodynamic markers and for molecular profiling analysis. In this Opinion article, we discuss recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites, particularly in the context of ovarian cancer.